Associated features in females with an FMR1 premutation by Wheeler, Anne et al.
Wheeler et al. Journal of Neurodevelopmental Disorders 2014, 6:30
http://www.jneurodevdisorders.com/content/6/1/30REVIEW Open AccessAssociated features in females with an FMR1
premutation
Anne C Wheeler1,9*, Donald B Bailey Jr1, Elizabeth Berry-Kravis2, Jan Greenberg3, Molly Losh4, Marsha Mailick3,
Montserrat Milà5, John M Olichney6,8, Laia Rodriguez-Revenga5, Stephanie Sherman7, Leann Smith3,
Scott Summers6,8, Jin-Chen Yang6,8 and Randi Hagerman6,8Abstract
Changes in the fragile X mental retardation 1 gene (FMR1) have been associated with specific phenotypes, most
specifically those of fragile X syndrome (FXS), fragile X tremor/ataxia syndrome (FXTAS), and fragile X primary
ovarian insufficiency (FXPOI). Evidence of increased risk for additional medical, psychiatric, and cognitive features
and conditions is now known to exist for individuals with a premutation, although some features have been more
thoroughly studied than others. This review highlights the literature on medical, reproductive, cognitive, and
psychiatric features, primarily in females, that have been suggested to be associated with changes in the FMR1
gene. Based on this review, each feature is evaluated with regard to the strength of evidence of association with
the premutation. Areas of need for additional focused research and possible intervention strategies are suggested.
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The fragile X mental retardation 1 (FMR1) gene was dis-
covered in 1991, and named as such for its role as the
causative gene for fragile X syndrome (FXS) [1-3]. Over
the last two decades since its discovery, significant ad-
vances have been made in understanding the phenotypic
expressions of mutated FMR1 alleles. The primary muta-
tion known to cause FXS results from an expansion of a
cytosine-guanine-guanine (CGG) trinucleotide repeat se-
quence in the first exon and promoter of FMR1. The re-
peat sequence is located in the 5′ untranslated region of
the FMR1 mRNA, and thus is not translated and does
not affect the sequence or structure of its encoded prod-
uct, the Fragile X Mental Retardation Protein (FMRP).
Normal alleles are considered to have between 5 and 44
CGG repeats, alleles with 45 to 54 repeats are intermedi-
ate or ‘gray zone’, 55 to 200 repeats constitute a ‘premu-
tation’ and 200 or more repeats, a ‘full mutation’.* Correspondence: acwheeler@rti.org
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unless otherwise stated.An individual with a full mutation is considered to
have FXS, which results from hypermethylation of the
promoter, silencing of the FMR1 gene and subsequent
decrease or absence of production of FMRP, which is ne-
cessary for healthy brain maturation. The phenotype of
FXS includes intellectual disability (ID), hyperarousal, so-
cial difficulty, anxiety, aggression, and autism spectrum
disorder (ASD) or autism traits [4]. The FXS phenotype is
not described in detail here; however, literature on the im-
pact of the challenging behavioral characteristics of FXS
on family members with a premutation is included where
applicable.
The premutation was historically thought to be associ-
ated only with risk for instability in the gene from gener-
ation to generation, and for children or grandchildren
with FXS, and not to specifically mediate disease in the
premutation ‘carriers’ themselves. However, research on
the premutation phenotype over the last 10 to 15 years
has demonstrated clear health risks associated with
FMR1 expansions in the premutation range. Two known
disorders - fragile X-associated primary ovarian insuffi-
ciency (FXPOI) and fragile X-associated tremor/ataxia
syndrome (FXTAS) have now been well documented
[5,6]. These conditions are known to exist in a subset of
individuals with a premutation, with specific associatedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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emotional and cognitive challenges have also been de-
scribed as occurring at a greater frequency among indi-
viduals with a premutation than would be expected in
the general population, although the association of the
premutation with many of these conditions is less well
established. Why some individuals with the premutation
are unaffected and others have symptoms may relate to
a number of factors, including the CGG repeat length,
magnitude of elevation of toxic CGG repeat-containing
FMR1 mRNA. Also possibly implicated are antisense
FMR1 transcripts, low FMRP levels, (particularly in the
upper premutation range), byproducts of aberrant trans-
lation of the repeat sequence including polyglycine-
containing peptides, genomic changes in the rest of the
genome, and environmental factors including toxins or
other exposures that may be harmful to the brain and
stress in families with fragile X associated disorders.
There is a suggestion of a continuum of involvement
with mild anxiety or shyness in some children or adults
with the premutation to more severe psychiatric prob-
lems and as carriers age, appearance of neurological
problems that may eventually result in FXTAS [6].
Understanding the phenotype associated with the pre-
mutation is important from a public health perspective,
given its prevalence. In the three US population-based
studies of the prevalence of CGG expansions, a higher
prevalence was observed than previously reported (1 in
151 women and 1 in 468 men [7]; 1 in 209 women and
1 in 430 men [8]; 1 in 148 women and 1 in 290 men [9].
This prevalence translates into over 1 million premuta-
tion carriers in the United States. The world literature
reveals considerable ethnic variability of prevalence of
the premutation, ranging in males from 1 in 1,674 in
Japan to 1 in 251 in Spain, and in females from 0 de-
tected in 324 tested cases in Japan to 1 in 113 in Israel
(reviewed in [7]).
This paper provides a review of features described in
the literature as being more prevalent in individuals, es-
pecially females, with a premutation. We approach this
review with a focus primarily on features seen outside of
the known diagnoses of FXS, FXTAS, and FXPOI, in
order to identify additional conditions that may be dir-
ectly associated with an FMR1 expansion; however, we
compare the relative strength of evidence for each fea-
ture among those with and without FXTAS or FXPOI in
the tables. As there is more literature describing these
features in females, we focus primarily on women; how-
ever, where mixed gender studies have been conducted,
evidence of these features in males is also described.
Similarly, we focus on the more extensive literature on
adults with a premutation with reference where appro-
priate to studies that have included children. Where evi-
dence or the suggestion of a relationship with CGGrepeat length has been found, this relationship has been
noted in the tables.
Based on the review of the literature and expert nomi-
nations from direct clinical experience, we describe
medical, cognitive, and psychiatric features in females
and rate each with the following criteria: 1) ‘definitely re-
lated’ indicating clear evidence of an association in un-
biased or minimally biased groups of carriers relative to
well-matched controls in several independent studies; 2)
‘probably related’ suggesting strong evidence of an asso-
ciation but either only one study, some conflicting evi-
dence or a need for studies examining the broader
population (for example, those not clinically ascertained);
3) ‘possibly related’ indicating emerging or anecdotal evi-
dence of an association with more extensive research
needed; or 4) ‘not likely related’ suggesting strong evidence
of an absence of an association through direct examin-
ation. These ratings are not meant to be definitive; rather
to assist in guiding future targeted research.
Medical features
Immune mediated disorders
A variety of medical problems besides FXTAS and
FXPOI have been reported to occur more frequently in
premutation carriers ascertained from clinical popula-
tions, as compared to noncarrier controls. Thyroid prob-
lems were found in 17.3% of non-FXTAS female carriers
(not significantly different from controls), but in 50% of
women with FXTAS, which was a significantly higher fre-
quency than in age-matched controls [10]. A study of fe-
male carriers by Rodriquez-Revenga et al. [11] also found
a significant increase in thyroid disease, as did results from
a large national survey of female carriers [Wheeler, A.C,
Bailey D.B., Raspa M., unpublished data]. Comparison
between nonclinically referred premutation carriers
and non-carriers ages 18 to 50 showed an increase to
10% from 5%, but this was not statistically significant
[12]. Thus, this association may be important in older
women. Irrespective, these problems may include
either a history of Hashimoto’s thyroiditis leading to
hypothyroidism or occasionally, Graves’ disease. These
problems are immune-mediated disorders (IMD) and
they are one of several such problems that have been
reported in female carriers [13]. Winarni et al. [13]
studied 344 adult female carriers ascertained from fra-
gile X families and found that 44.7% suffered from an
IMD compared to 27.8% of controls. The odds ratio of
having an IMD was significantly elevated both in fe-
males with FXTAS (OR = 5.5) and without FXTAS
(OR = 2.1) from this cohort compared to controls [13].
Fibromyalgia symptoms
In the study of IMD [13], autoimmune thyroid disorders
were the most common problems overall (24.4%) followed
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different compared to a limited number of controls
(n = 72). However, two recent studies of FMR1 muta-
tions among women with fibromyalgia in Spain have
reported conflicting findings, with one study of 353
women finding an increased rate of FMR1 premuta-
tions, while a second study of 700 women did not find
an association [14,15]. More research is needed in
this area.
Hypertension
Hypertension was first noted by Coffey et al. [10] in a
survey of 146 premutation female carriers ascertained
from fragile X families in clinic. In a large national sur-
vey of women with a premutation, 15.1% of women re-
ported a diagnosis of hypertension, which was significantly
lower than national occurrence rates [Wheeler, A.C, Bailey
D.B., Raspa M., unpublished data]. Similarly, hypertension
was seen in 16.4% of women without FXTAS which was
not different from age-matched controls (10%). However,
hypertension was seen in 61% of females with FXTAS, a
significantly higher frequency than 18%, observed in age-
matched controls. Hypertension may be considered an
autonomic problem associated with premutation-mediated
toxicity related to FXTAS.
Migraines
Migraines are common among carriers and they occur
in both males and females. In a single study of 315 car-
riers (203 females and 112 males) compared to 154 con-
trols, a diagnosis of migraines was seen in 54.2% of
female carriers, significantly different from female con-
trols (25.3%) [16]. Smith, Seltzer, and Greenberg [17] re-
ported that headaches (not specifically migraines) were
significantly more common among premutation carrier
mothers of children with FXS (26.9%) than matched
controls (13.6%) who did not have children with disabil-
ities. Of note, headaches were not significantly increased
in carriers ascertained from the general population com-
pared to controls in Seltzer et al. [7], so this may imply
a relationship between migraines in families ascertained
in clinic and family stress issues. Migraines can be asso-
ciated with some syndromes resulting from mitochon-
drial dysfunction, which has been observed in cell lines
from premutation carriers [18,19]. As with the general
population, the onset of migraines is typically in teenage
or young adult years and migraine prevalence decreases
with age [16].
Neuropathy
Neuropathy was first reported in female premutation
carriers in a series of five case reports of females with
FXTAS, of whom four had signs of neuropathy on exam-
ination [20]. In a subsequent neuropathological caseseries [21] of eight women with the premutation with or
without FXTAS, three were noted to have neuropathy.
One of these women had chemotherapy with multiple
neurotoxic agents, making it difficult to determine
whether the neuropathy related to the premutation,
and one had multiple sclerosis with likely central
symptoms complicating assessment of nerve disease.
One of the women, however, did have neuropathy with
no obvious cause other than the premutation.
Several studies have examined neuropathic signs and
symptoms in large groups of carriers relative to controls.
Berry-Kravis et al. [22] found a significantly higher nu-
merical neuropathy score based on examinations of 73
female premutation carriers relative to 32 age-matched
control women, but this finding did not achieve statis-
tical significance. The neuropathy score correlated with
CGG repeat length after controlling for activation ratio,
suggesting a relationship of neuropathic signs to the pre-
mutation. Neuropathy scores also correlated with the
ataxia subscore on the FXTAS rating scale, suggesting
that carriers beginning to have signs of FXTAS are more
likely to have neuropathic signs than those without signs
of FXTAS. Coffey et al. [10] studied 128 female carriers
without FXTAS, 18 carriers with FXTAS and 69 controls,
and found a significant rate of numbness and tingling and
muscle pain in the extremities in both women with
FXTAS and also in those without FXTAS compared to
controls. However, neurological examination showed there
was rarely sensory loss or evidence of neuropathy in
women without FXTAS. Evidence of neuropathy upon
examination was increased in carriers with FXTAS as
compared to controls and to carriers without FXTAS. Car-
rier women without FXTAS also reported a history of
intermittent tremor in 11%, significantly higher than the
controls with 1.5% [10]. Therefore, symptoms of neuro-
logical problems by history are more common than what
is documented by neurological examination, presumably
because symptoms may be very intermittent early on and
persistent findings only occur when the CNS changes are
more significant. In Chonchaiya et al. [23], a structured
questionnaire was administered to 110 female carriers
who were daughters of a parent with FXTAS, 36 female
carriers without a parent with FXTAS, and 43 controls.
Neuropathic symptoms in the arms and legs were more
frequently reported by carriers with and without parents
with FXTAS than by controls. Two other studies found a
significantly higher prevalence of neuropathic symptoms.
Seltzer et al. [7], in a population based sample, reported
that 29% of premutation carriers reported numbness (ver-
sus 13% of controls), and Smith et al. [17] found that
26.6% of premutation carrier mothers of full mutation
children with FXS experienced muscle soreness (versus
16.6% of controls). Hunter et al. [12] did not find an in-
crease in reporting of musculoskeletal symptoms by
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not specifically ask about neuropathic symptoms. Based
on the literature, it seems that neuropathy is clearly re-
lated to carrier status in female carriers but may not be-
come manifest until symptoms of FXTAS also begin to
emerge.Vestibular issues
Vestibular complaints with a feeling of spinning, sud-
denly being unbalanced, and difficulty with ‘equilibrium’
are commonly reported complaints voiced by female
premutation carriers. In Chonchaiya et al. [23] dizziness
was reported more frequently by carriers with or without
a parent with FXTAS than by noncarrier controls, and
balance problems by carrier women with a parent with
FXTAS more frequently than by carriers with no parent
with FXTAS or controls. Smith et al. [17] reported sig-
nificantly higher rates of dizziness in premutation carrier
mothers of children with FXS (5.0%) than controls (1.3%),
and this was also reported by Seltzer et al. [7] who found
that dizziness and faintness were experienced by 18% of
premutation carriers in a population-based sample, signifi-
cantly higher than controls (4%). Recent quantitative stud-
ies using computerized dynamic posturography (CDP), a
‘gold standard’ balance assessment tool that has been
shown to be highly sensitive, have shown impairments
relative to control standards in a small group of female
premutation carriers with the vestibular conditions of the
sensory organization test and with the motor control and
limits of stability test [24]. Vestibular deficits appeared to
be present in carriers who did not meet clinical criteria for
FXTAS, but were correlated with FXTAS motor rating
scale scores and were more severe in those with FXTAS.Other symptoms
In addition to the symptoms reported above, Smith
et al. [17] reported significantly higher rates of backache
and fatigue in premutation carrier mothers of full muta-
tion children with FXS than in controls.Table 1 Medical/health features examined in premutation car
Medical/health
features
Strength of evidence-those
with FXTAS
Strength of ev
o
Thyroid Disease Probably related Poss
Hypertension Possibly related Poss
Fibromyalgia
symptoms
Probably related Poss
Migraine Possibly related Poss
Neuropathy Definitely related Prob
Vestibular difficulties Probably related Prob
FXTAS- fragile X-associated tremor/ataxia syndrome.Table 1 summarizes nominations for medical/health
features for women with a premutation with and without
a diagnosis of FXTAS.
Reproductive features
Ovarian insufficiency
Female premutation carriers are known to be at increased
risk for Fragile X-associated Primary Ovarian Insufficiency
(FXPOI). FXPOI encompasses premature ovarian failure,
or cessation of menses prior to age 40, and other indica-
tors of early ovarian aging or dysfunction [25]. On average,
the age at menopause among premutation carriers is 5
years earlier than in the general population of women
[5,7,26]. Smith et al. [17] also reported significantly higher
rates of hot flashes or flushes in premutation carriers
(15.4%) than controls (6.9%). CGG repeat size has been
found to be associated with the risk of earlier menopause
but in a non-linear manner, with the highest risk for
those with mid-range repeats (approximately 70 to
100) [5,27-30].
Among women who are still cycling, hormonal changes
associated with FXPOI are noted more often in women
with the premutation compared with controls. These in-
clude decreased levels of anti-Müllerian hormone (AMH)
and increased levels of follicle stimulating hormone (FSH),
among others [5,26,29,31-33]. Other signs of early ovarian
aging include irregular, shorter or skipped cycles and sub-
fertility [27,32].
Fertility issues
The most immediate and significant consequence of POI
is reduced fertility [27,34]. Given the higher rates of
early menopause, difficulty with fertility is significant
for women with a premutation. Even among younger
women, difficulty getting pregnant has been reported
at higher than expected rates among women who are
premutation carriers [27]. In a large national survey
study of families affected by FX, female premutation
carriers reported a significantly higher rate of use of
assistive reproductive technology (for example, fertilityriers
idence-asymptomatic
f FXTAS
Strength of evidence - association with
genetic markers
ibly related Possible association with CGG repeat length
ibly related Possible association with CGG repeat length
ibly related Possible association with CGG repeat length
ibly related Not found to be associated with CGG repeat
length
ably related Severity related to CGG repeat length after
controlling for AR
ably related Relationship not yet examined
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seen in the national occurrence rates [Wheeler, A.C,
Bailey D.B., Raspa M., unpublished data]. Similar to
the other symptoms of FXPOI, fertility problems ap-
pear to be most significant for women in the mid-
range CGG group [27].
Obstetric and perinatal difficulties
Despite known challenges with fertility, very little is
known regarding potential obstetric or perinatal risks for
FMR1 premutation carriers. One study, conducted in
Finland, examined pregnancy outcomes in 63 women
who were premutation carriers compared to the general
obstetric population [35]. The authors of this study
found a slightly higher risk for late pregnancy bleeding
in the FMR1 premutation, but no other concerns related
to the course or outcome of pregnancy. In a large na-
tional survey study [Wheeler, A.C, Bailey D.B., Raspa M.,
unpublished data] a significantly higher rate of reported
preeclampsia was found in premutation carrier women
than would be expected based on national occurrence
rates in the United States. More research is needed to
determine whether women with a premutation experi-
ence greater pregnancy or birth risks.
Estrogen-deficiency related conditions
In general, the state of early estrogen deficiency resulting
from POI leads to an increased risk for low bone density,
earlier onset osteoporosis and bone fractures [36], impaired
endothelial function [37], earlier onset of coronary heart
disease [38], and increased cardiovascular mortality. Among
premutation carriers, lower bone mineral density [39] and
osteoporosis [27] is reported at a high frequency than
among non-carriers, but not other estrogen deficiency re-
lated disorders.
Hypoestrogenism may have behavioral and cognitive
consequences as well. Women with an earlier age at meno-
pause are reported to have more anxiety, depression,
somatization, sensitivity, hostility, and psychological dis-
tress than women with normal ovarian function [40]. SomeTable 2 Reproductive features examined in female premutati
Reproductive features Strength of evidence - those
with FXPOI
Stre
with
Ovarian insufficiency Definitely related Defi
Estrogen-related
conditions
Definitely related Poss
Fertility issues Definitely related Defi
Obstetric and perinatal
difficulties
Possibly related Poss
Postpartum depression Possibly related Poss
FXPOI- fragile X-associated primary ovarian insufficiency.studies have found suggestive evidence that symptoms of
FXPOI may partially explain the increased vulnerability for
mood disorders [41] and anxiety and depression [12].
Given the altered hormone profiles and the stress related
to being a carrier of the premutation (for example, add-
itional potential stress of having a newborn with FXS), post-
partum depression would seem to be of great concern. Very
few studies have specifically examined increased risks for
PDD in women with a premutation. Wheeler et al. [unpub-
lished data] found that rates of self-reported postpartum de-
pression among women with a premutation were not higher
than is found in national occurrence rates. However, among
those who had experienced PPD, 41.18% experienced at
least 2 episodes. In a study of 50 women with a premutation
who also had children and a history of major depressive dis-
order, there was a significant increase in risk for PDD
among women with more than one child with FXS [42].
Therefore it may be the cumulative stress of having multiple
children with FXS that increases risk for PDD, rather than
premutation status. More research is needed in this area.
The question of whether or not endogenous or ex-
ogenous estrogen (from replacement therapy) is related
to indicators of neurocognitive deficit is unresolved
(reviewed in [43]). The statistically significant association
of reduced Verbal IQ and a crude measure of estrogen
status among premutation carriers suggests further stud-
ies should be done [44].
Estrogen also plays a role in immune-response and in-
flammation and has been implicated in the onset of auto-
immune disorders [45], a class of disorders reported to be
elevated among women who carry the premutation carries
as noted above. Lastly, estrogen has been shown to moder-
ate the impact of chronic stress on mood and psychiatric
outcomes [46] a role of particular interest given that women
with the premutation often experience high levels of stress
related to their role as primary caretakers of children with
fragile X syndrome and older relatives with FXTAS.
Table 2 summarizes nominations for reproductive fea-
tures for women with a premutation with and without
probable FXPOI.on carriers with and without FXPOI
ngth of evidence-those
out FXPOI
Strength of evidence - association
with genetic markers
nitely related Strong evidence of nonlinear associate
with CGG
ibly related Possible association with CGG repeat
length
nitely related Strong evidence of nonlinear associate
with CGG
ibly related Relationship not yet examined
ibly related Relationship not yet examined
Wheeler et al. Journal of Neurodevelopmental Disorders 2014, 6:30 Page 6 of 14
http://www.jneurodevdisorders.com/content/6/1/30Neurocognitive features
Various cognitive domains have been reported to be af-
fected by the premutation even in those without FXTAS.
These domains include executive function [47,48], work-
ing memory [49], and arithmetic [50]. These deficits can
appear even in young individuals and often show a more
progressive course in premutation carriers than in the
general population. This may be an early sign of the
often significant cognitive impairment, primarily in the
realm of executive dysfunction that can accompany
FXTAS [51]. However, it must be noted that some stud-
ies have not found these areas of weakness. Most likely
there is a subset of women with the premutation who
are more vulnerable to effects of the premutation.
General intelligence
Several studies have found normal overall cognitive abil-
ities in non-FXTAS female adult premutation carriers
who underwent general intelligence tests (most com-
monly the Wechsler scales) [47,52-56]. A recent study in
older female premutation carriers over age 50 also
showed normal IQ scores [57]. In contrast, a few reports
have documented lower verbal IQ scores among these
women compared to female normal controls [44,58] or
their male counterparts [59], with CGG repeat length
explaining approximately 4% of the variance of verbal
IQ per linear regression [44]. Case studies have shown
mixed results as well, with low [60,61] and superior [62]
IQ scores both observed in girls with the premutation.
Myers and colleagues [63] examined 14 children (7 female)
and found a trend towards lower performance IQ, a meas-
ure closely related to executive functioning. Arithmetic
difficulties have also been reported in females with the pre-
mutation [50,58].
Executive function
Executive function involves the capacity for self-regulation
of behavior and attention, and consists of multiple pro-
cesses including maintaining and updating relevant infor-
mation in working memory, inhibition of irrelevant
information, switching task goals, and performance
monitoring [64,65]. Although executive function has
been regarded as the primary cognitive domain af-
fected in patients with FXTAS [50,66], several studies
of non-FXTAS female premutation carriers in young
adulthood and midlife have reported normal scores on
widely-used executive functioning tests such as the
Wisconsin Card Sorting Test (WCST), Trail Making Test
(TMT) and Stroop Color and Word Test [52,54,55,67].
Whereas, in a study involving older female premutation
carriers up to 76 years of age (mean age = 41) [47], execu-
tive function, as measured by the Behavioral Dyscontrol
Scale (BDS) [68], was modulated by premutation CGG re-
peat length and/or FMRP level after controlling for full-scale IQ scores (FSIQ). By examining event-related brain
potentials (ERPs) in older female premutation carriers,
Yang et al. [57] found poorer BDS performance correlated
with decreased amplitude of the frontal P300. This ERP
component is thought to index selective attention and
working memory updating processes, which may underlie
the executive dysfunction in both males and females with
FXTAS [57,69]. Thus, executive dysfunction likely pre-
sents as a late-onset phenotype affecting non-FXTAS
female premutation carriers over age 50 in addition to
non-FXTAS premutation males [48,66]. It is also worth
noting that both of the two studies [47,57] with find-
ings of executive dysfunction have controlled for FSIQ
as a covariate.
Attention
Sustained attention in a visual search task was compar-
able among non-FXTAS females with the premutation
and various control groups [58]. A large sample of fe-
males with the premutation had more self-reported at-
tention deficits than controls without a mutation [55].
Attention involved in enumerating 5 to 8 rectangles was
shown to be modulated by both premutation CGG re-
peat length and age [70].
Memory
Verbal memory generally remains intact in non-FXTAS
female premutation carriers [55,57,58,67], but one case
study reported substantially impaired verbal memory
functions in a 72-year-old old woman [71]. Both imme-
diate and delayed recall of visual memory has been
shown to be affected by the premutation CGG repeat
length in these carriers [47]. In a functional magnetic
resonance imaging (MRI) experiment using a working
memory task, carriers of both genders showed reduced
frontal activation regardless of FXTAS diagnosis [72].
Interestingly, Yang et al. [57] found impairments in
some measures of working memory in non-FXTAS fe-
male carriers that were not present in females with
FXTAS.
Language issues
As noted earlier, studies assessing global indices of ver-
bal ability such as verbal IQ, have generally reported that
premutation carriers who are not affected by FXTAS ex-
hibit comparable abilities as matched controls or normed
references (reviewed in [12]). In contrast, results from the
few studies that have assessed functional language (or, the
use of language in social contexts, for example, conversa-
tional ability) suggest that such language skills may be im-
pacted among premutation carriers. Sterling et al. [73]
elicited brief language samples collected from a group of
nearly 200 women with the premutation and assessed
samples for different types of dysfluencies, including
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excessive fillers (for example, um, ah, oh), and revisions to
correct or modify a prior utterance. These types of dys-
fluencies could reflect problems with executive skills such
as planning and organization, and can interfere with fluent
communication. As such, they may represent clinically
meaningful phenotypes. In this study, the rate and types
of dysfluencies were compared between women with the
premutation and women who were parents of individuals
with autism, included to control for the stress of caring
for a child with a disability, which the authors hypothe-
sized could impact fluency. Analyses revealed significantly
higher rates of all types of dysfluencies among the premu-
tation carrier group (compared to the mothers of children
with autism), as well as a significant association with age
(increased dysfluencies with greater age). There was no as-
sociation with CGG repeat length, and other molecular
variables were not examined. Losh et al. [74] also reported
elevated rates of subtle conversational differences among
premutation carrier women, further suggesting that lan-
guage may be affected in the premutation.
Table 3 summarizes nominations for cognitive features
in females with a premutation with and without a diag-
nosis of FXTAS.
Psychiatric features
Affective disorders
Mood disorders have been a concern in the fragile X
premutation population for over two decades. Initial
small studies in women failed to demonstrate meaning-
ful difference between carriers and controls in depressive
disorders [52,75]. However, these studies were small,
limited by the screening tools and by poor recall. Later,
much larger research studies did demonstrate a relation-
ship between the number of CGG repeats and the pres-
ence of depression [76] as well as the severity of
depressive symptoms [77]. When comparing 93 womenTable 3 Cognitive features examined in female premutation c
Cognitive
features
Strength of evidence- those
with FXTAS
Strength of evid
of
Low IQ Definitely related Proba
Arithmetic
difficulties
Definitely related Proba
Executive
dysfunction
Definitely related Proba
Attention deficits Definitely related Possi
Verbal memory Definitely related Not lik
Verbal working
memory
Definitely related Proba
Visual memory Definitely related Proba
Language Definitely related Proba
FXTAS- fragile X-associated tremor/ataxia syndrome.with the premutation screened using the strict criteria of
the structured clinical interview for the DSM-IV (SCID)
to a large national databank, the lifetime prevalence of
major depressive disorder was 43.0% versus 31.9% [50].
Although Seltzer et al. [7] did not find evidence of ele-
vated prevalence of depressive symptoms in a population-
based sample, and Smith et al. [17] similarly did not
report elevated rates of negative affect in premutation
carriers than controls. Seltzer et al. [78] reported evi-
dence of higher rates of depressive and anxiety symp-
toms in premutation carrier mothers of full mutation
children with FXS under certain genetic and environ-
mental conditions: mothers who experienced stressful
life events in the previous year had higher rates of de-
pression and anxiety if their CGG repeats were in the
mid-range of CGG repeats. Dysthymia and bipolar dis-
order have generally failed to demonstrate significant
levels in carriers compared to controls [79].
Autism spectrum disorders
Because FXS is one of the most common single-gene
disorders associated with autism, investigation has been
undertaken to determine what risk the carrier state con-
fers. In a screening study of individuals from families
with FXS, roughly 14% of boys and 5% of girls with the
premutation were found to also have an autism spectrum
disorder (ASD) [80]. Even among those carriers not diag-
nosed with ASD, related psychological traits are more
common among carriers compared to controls without
the premutation. A relatively large body of research has
now documented differences among parents and relatives
of individuals with autism, constituting a broad autism
phenotype, or, a constellation of mild behavioral features
that resemble the features of autism in quality but that are
more subtly expressed and not typically associated with
functional impairment (reviewed in [81]). A recent study
examined a broad range of pragmatic language skills asarriers with and without FXTAS
ence-asymptomatic
FXTAS
Strength of evidence - association with
genetic markers
bly related Possible association with CGG repeat length
bly related Possible association with CGG repeat length
bly related Probable association with CGG repeat length
bly related Probable association with CGG repeat length
ely related Possible association with CGG repeat length
bly related Possible association with CGG repeat length
bly related Possible association with CGG repeat length
bly related Not found to be associated with CGG
repeat length
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phenotype among women with the premutation, com-
pared with mothers of children with autism, and mothers
of typically developing children with no family history of
fragile X, autism, or language impairment [74]. In this
study, conversational samples from a videotaped semi-
structured interview were used to assess pragmatic lan-
guage using the Pragmatic Rating Scale (PRS) [82]. This
study replicated previous findings in the autism parent
group and also showed that women with the premutation
exhibited similarly elevated rates of pragmatic language
problems relative to controls. Factor analysis of items on
the PRS revealed that premutation carriers committed the
same types of pragmatic language violations as parents of
individuals with autism. Such similarities in pragmatic lan-
guage profiles could suggest that the differences between
these groups stem from similar underlying factors, sup-
porting a link between FMR1 and autism-related pheno-
types in carrier relatives. In support of this possibility, the
study also found that premutation carriers displayed ele-
vated rates of personality traits associated with the broad
autism phenotype, rigid or inflexible traits and socially reti-
cent dispositions. The presence of broad autism phenotype
traits was associated with greater expression of autism
symptoms in their children with FXS. Other studies have
also found increased rates of both social aloofness [83] and
a rigid perfectionism [84] among carrier women. Studies
have shown that amygdala dysfunction in viewing social
stimuli seen in carriers correlates with clinical findings of
social deficits and both FMRP deficits and elevated FMR1
mRNA levels [85].
Anxiety
The largest and most recent study of life-time mood and
anxiety in the premutation population was completed by
Bourgeois et al. [79]. In that study, carriers both suffer-
ing and not suffering from FXTAS were compared in
the prevalence of anxiety disorders to a very large age-
matched national dataset. In terms of all anxiety disor-
ders, only those suffering from FXTAS demonstrated a
higher prevalence. When separated out, this was simi-
larly true for panic disorder, post-traumatic stress dis-
order and specific phobia. Generalized anxiety disorder
and obsessive compulsive disorder failed to demonstrate
any difference between carriers and controls. Only social
phobia was found to have higher levels in premutation
carriers without FXTAS compared to controls. Chronic
anxiety has also been associated with radiological signs
on MRI; specifically, the higher the anxiety score the
smaller the size of the hippocampus in women with the
premutation [86].
Other reports have not found high levels of mental
health problems; however, differences in measurements
(life-time versus state traits, interview versus self-report),age of participants, ascertainment of participants, etcet-
era, will all play a role in explaining such differences.
Irrespective, continued research to identify vulnerable
women is essential.Psychosis
Psychosis, given its relative rarity in the general popula-
tion, has been challenging to study in premutation car-
riers. Initial linkage analysis failed to show a clear
relationship of schizophrenia to the FMR1 gene [87].
Prevalence studies have found the overall rate of psych-
otic disorders to be low [83]. There have, however, been
several case reports of combined psychotic illnesses and
the premutation, including schizoaffective disorder [88]
and a subject with combined schizophrenia and schizoid
personality disorder [89]. Interestingly, as opposed to
frank psychotic disorders, multiple studies have found
increased prevalence of schizotypal personality traits in
the carrier population [83,90].Attention deficit/hyperactivity disorder
Attention regulation difficulties have been proposed to
be a problem in people with the premutation. Notably,
when compared with their control siblings, premutation
carriers had significantly more issues with attention than
their noncarrier siblings [91]. Inattention and impulsivity
amongst FMR1 carriers can be problematic through
adulthood [55], although hyperactivity was not noted to
be increased in prevalence. In an analysis to examine the
genetic architecture of ADHD symptoms in families with
FXS, it was found that the FMR1 repeat accounts for
about 5% of the variance whereas polygenes account for
about 50% of the residual variance. This suggests that
the premutation acts in concert with additional genetic
loci to influence the severity of ADHD symptoms [92].Sleep and related problems
Sleep issues have recently been studied in carriers, and
common measures such as the Pittsburgh Sleep Quality
Index and the Insomnia Severity Index have shown sig-
nificant pathology. These findings may be related to
higher rates of Restless Legs Syndrome and sleep apnea,
both of which have shown multiple-fold increases in
subsets of the premutation population [93,94]. Sleep
apnea is common in older carriers with FXTAS. In a
study of 229 males and 201 females with the premuta-
tion, including 118 with FXTAS and 123 controls, sleep
apnea occurred in 31.4% of carriers with FXTAS, 8.6% of
carriers without FXTAS and in 13.8% of controls by
medical history [93]. These issues may be contributing
to the development of significant fatigue, which is a
common complaint of adult carriers [95].
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Two hypotheses have been advanced to account for ele-
vated psychiatric, cognitive, and somatic symptoms in
premutation carriers [96]: first, that such symptoms are
a primary biological feature of FMR1 CGG expansions
in the premutation range, and second, that such symp-
toms may be exacerbated by the stress associated with
parenting a child with FXS. Importantly, stress may
interact with the biological vulnerabilities caused by the
premutation, and thus it is important to incorporate bio-
logical markers when exploring stress effects in this
population.
Parenting stress It has been well established that many
individuals with FXS have severe behavior problems, in-
cluding inattention, hyperactivity, aggression, anxiety,
and autism symptoms [97], which result in high levels of
stress exposure for their families [96,98-102]. In one
study, exposure to child behavior problems was investi-
gated in the context of a biomarker of the premutation,
namely the activation ratio. Hartley et al. [103] studied
the prevalence of daily behavior problems in adolescents
and adults with FXS who were living with their families,
and found that during an 8-day period, 85.7% exhibited
at least one episode of significant behavior problems,
such as behaviors that were disruptive, aggressive, de-
structive, self-injurious, unusual or repetitive, socially
offensive, uncooperative, or inattentive. Such episodes
occurred, on average, about every other day.
The effects of this level of stress exposure were evident
in the mother’s level of cortisol, a stress hormone that
previously has been shown to be depressed in mothers
of children with developmental disabilities, including
autism [104,105]. Hartley et al. [103] found that premu-
tation carrier mothers who had a low activation ratio
(AR; that is, a low proportion of cells expressing the nor-
mal allele) showed an atypical response to their child’s
behavior problems. Specifically, for mothers with a low
AR, the greater the number of behavior problems mani-
fested by their child the previous day, the lower the
mother’s cortisol level the next morning, which is an
atypical response to acute stress. In contrast, for mothers
with a high AR (that is, a larger proportion of cells ex-
pressing the normal allele), the greater the number of
child behavior problems the previous day, the higher the
mother’s morning cortisol, which is a more normative
neuroendocrine response to environmental stress. Also,
mothers who had more than one child with FXS had
lower cortisol levels than those who had ‘only’ one af-
fected child, further supporting the toll that stressful
parenting takes on neuroendocrine functioning in carrier
mothers.
Hunter et al. [106] hypothesized that among women
with the premutation, the stress of raising a child withFXS may be moderated by genetic factors influencing
endogenous cortisol responses, which could in turn
modulate mental health symptoms. They examined the
association of genetic variation in the corticotrophin re-
leasing hormone receptor 1 locus (CRHR1) in 460 women,
including premutation carriers with and those without a
child with FXS and non-carriers. A statistically significant
interaction between the CRHR1 genotype and the status
of raising a child with FXS was associated with social anx-
iety symptoms as reported on the Social Phobia and Anx-
iety Inventory (SPAI). These preliminary data suggest that
there may be a subgroup of premutation carriers who are
more susceptible to the effects of stress.
Stressful life events Stressful life events are a source of
stress quite distinct from child behavior problems, and
include experiences such as divorce, death of a family
member or close friend, caring for an aging parent, or
negative changes in financial or health status. These life
events have been shown to compromise psychological
well-being in the general population [107] and in parents
of children with developmental disabilities [108,109]. Al-
though exposure to child-related stress is a common
characteristic of premutation carrier mothers of children
with FXS, these mothers vary with respect to their ex-
posure to other types of stress.
Only one study has been conducted investigating gen-
eral life stress effects in premutation carrier mothers of
children with FXS. Seltzer et al. [78] found that during
the previous year, two-thirds (68.3%) reported having ex-
perienced at least one negative life event. However, the
other mothers did not experience any of these sources of
life stress during the previous year. The variation in ex-
posure to life events made it possible to investigate the
effect of exposure to this type of stress on premutation
carrier mothers of children with FXS.
Specifically, Seltzer et al. [88] investigated the effects
of exposure to stressful life events with respect to de-
pressive and anxiety symptoms as well as cortisol level
in premutation carrier mothers. They found that the
higher number of stressful life events experienced during
the previous year, the greater the level of depression and
anxiety, and the lower the level of cortisol. However,
variation in the biology of the premutation was critical
to understanding the pattern of stress effects. A curvilin-
ear association was observed between stress exposure
and CGG repeat length. Premutation carrier mothers
with mid-range CGG repeat lengths (approximately 90
to 105) had the highest levels of depression, anxiety, and
the most abnormal cortisol parameters if they had re-
cently experienced stressful life events, but mothers in
the same CGG repeat range had the lowest level of de-
pression and anxiety, and the most normal cortisol pa-
rameters if their life had been free from stressful events
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ent in the mid-CGG range, whereas those with low
CGG repeat numbers or repeats closer to the full muta-
tion cut-off were less reactive to stress. A curvilinear
pattern of vulnerability in CGG repeat effects has been
previously shown for reproductive outcomes in carrier
females [5,26,27] and for depression [56]. This study im-
plicates exposure to stressful life events and CGG repeat
length in the manifestation of psychiatric symptoms in
premutation carrier mothers.
A large number of studies have shown that autism is
an extremely stressful developmental disorder, arguably
the disorder posing the greatest level of parenting stress
[110,111]. A few studies have contrasted parenting stress
in mothers who have a child with autism and mothers
whose child has FXS [17,112]. These studies generally
have found similar patterns for premutation carrier
mothers of children with FXS and mothers of those with
autism. These findings of similarity between premutation
carrier mothers of children with FXS and mothers of
children with autism are similar to earlier work in which
it was found that the most consistent predictor of mater-
nal depression across disability groups (FXS, ASD, and
Down syndrome) was child behavior problems [113].
Only when research that separates the effects of the biol-
ogy of FMR1 expansions from the effects of stressful
parenting will there be a complete understanding of the
premutation phenotype and how stress may alter it.
Table 4 summarizes nominations for psychiatric fea-
tures in premutation carriers.
Conclusions
At this point there is strong evidence to suggest that fe-
males with an FMR1 premutation may be variably at risk
for multiple medical, reproductive, cognitive, and psychi-
atric difficulties. While there are clear phenotypes asso-
ciated with specific FMR1-related diagnoses (FXS,
FXTAS, FXPOI), there are many more diagnoses that
may be associated with the premutation and should be
considered whenever a premutation carrier presents to a
clinic. Several recent papers have described significance
and breadth of concerning features reported to beTable 4 Psychiatric features examined in female premutation
Psychiatric
features
Strength of evidence- those
with FXTAS
Strength of evidenc
of FXT
Affective disorders Probably related Probably
Anxiety Possibly related Possibly r
Autism traits Not examined Possibly r
Psychosis Possibly related Possibly r
ADHD Possible related Probably
Sleep issues Possibly related Possibly r
FXTAS- fragile X-associated tremor/ataxia syndrome.associated with the FMR1 premutation [6,11,114,115],
thus capturing the importance of better describing phe-
notypes associated with the premutation.
Based on this review of the literature, we have identi-
fied specific features thought to be at higher risk for pre-
mutation carriers as being ‘definitely related’ ‘probably
related’ ‘possibly related’ or ‘not likely related’ to the mo-
lecular changes associated with an FMR1 expansion.
While the rates of many medical and psychiatric prob-
lems are significantly increased in aging carriers who
have FXTAS [79], the onset of some of these problems
has been reported well before the onset of an official
diagnosis [116]. The emergence of some problems, such
as ADHD, anxiety disorders and autism traits are noted
to occur in some premutation carriers in childhood
[91,117,118]. However, little is known about the early
developmental phenotype of individuals with a premuta-
tion, and those studies that have focused on features in
children with a premutation are virtually all based on
clinically referred children or siblings of an individual
with FXS. Additional longitudinal studies are needed to
determine at what point some of these features may de-
velop, whether they are developmental or degenerative
and what protective factors might reduce risks for more
negative outcomes.
CGG repeat length has been implicated in the onset
and severity of several of these features. This is most
notable in the literature on FXPOI, with a nonlinear as-
sociation (greater severity among those with midrange
repeats) being reported in multiple studies [5,27,28,30].
Similar nonlinear findings have been reported for psy-
chiatric [12,56,78,119] symptoms, while other studies re-
port linear associations between repeat length and severity
of neurological symptoms [22,49,120]. There may be a
variable degree of RNA toxicity in carriers due to elevation
of the FMR1 mRNA, which can lead to oxidative stress
and neuronal hyperexcitability [121]. FMR1 mRNA level
increases with the length of the CGG repeat, and the ex-
panded repeat-containing mRNA makes hairpin loop
structures that appear to sequester important proteins for
neuronal function including Sam 68, DROSHA and DGCR8
[122,123]. These later two proteins are necessary forcarriers with and without FXTAS
e-asymptomatic
AS
Strength of evidence - association with
genetic markers
related Possible association with mRNA, CGG repeat length
elated Possible association with mRNA, CGG repeat length
elated Relationship not yet examined
elated Possible association with mRNA, CGG repeat length
related Possible association with mRNA, CGG repeat length
elated Relationship not yet examined
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tion and translation in the CNS [123]. The RNA tox-
icity is thought to be related to miRNA dysregulation
which can jeopardize survival of the neuron and glia
containing the premutation [124,125]. Additional re-
search is needed to examine the relationship between
these biomarkers and phenotypic features.
Also, cumulative effects of multiple risk factors may
occur. Those individuals with the premutation and ei-
ther intellectual disabilities, seizures or autism traits are
also likely to have a second genetic hit [R Lozano, RH,
and F Tassone, unpublished data]. Hypertension and
hypothyroidism, irrespective of the strength of the asso-
ciation with the premutation, should be evaluated med-
ically and if present, treated, since the lack of treatment
may aggravate CNS dysfunction. Neurological problems
including migraines, neuropathy, sleep apnea and psy-
chiatric problems should be considered and if present
and sufficiently symptomatic then treatment should be
initiated. Exercise, stress reduction techniques such as
therapy, biofeedback or meditation, avoidance of toxins,
such as excessive alcohol use or illicit drugs, avoidance
of vitamin deficiency and healthy eating should be rec-
ommended for all carriers [6].
It is important to note that almost all research describ-
ing the premutation carrier phenotype is based on indi-
viduals who were ‘reverse-ascertained’ from a child with
the full mutation in a clinical setting, and this potentially
confounds the effects of the premutation with the im-
pact of stressful parenting and referral bias. Thus, the lit-
erature may be skewed toward larger repeats, and more
serious symptoms, as well as substantial ascertainment
bias toward patients and families who are more likely to
seek medical care for themselves or their child with FXS,
and thus are more likely to have clinical symptoms.
Studies of premutation carriers who do not have chil-
dren with FXS and even who are not aware of their gen-
etic status would make it possible to address a central
unanswered question namely whether, in an unbiased
sample of individuals with FMR1 CGG expansions (who,
for example, are not exposed to stressful parenting, and
are not aware of literature related to their genetic sta-
tus), there are increased risks of clinical or sub-clinical
symptoms (neurocognitive, health, and psychiatric) and
whether the severity of such symptoms is associated
with their FMR1 genotype.Abbreviations
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